{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:22:54Z","timestamp":1793726574093,"version":"4.6.1"},"reference-count":28,"publisher":"SLACK, Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Orthopedics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>We characterize outpatient prescribing trends of orthopedic surgery providers in the United States.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods<\/jats:title>\n            <jats:p>A retrospective analysis of the Medicare Part D Prescribers - by Provider and Drug was conducted between 2013 and 2021, including anti-osteoporotic medications (AOMs), antibiotics, opioids, and nonsteroidal anti-inflammatory drugs (NSAIDs). Outcomes included claims, claims per 1,000 prescribers, combined annual growth rate, and percentage growth.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>\n              Claims for AOMs decreased from 29,024 in 2013 to 12,500 in 2021. Claims for alendro-nate, ibandronate, risedronate, and teriparatide all significantly decreased, whereas claims for abaloparatide and romosozumab significantly increased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05). Antibiotic claims increased from 304,817 (2013) to 580,736 (2021). Claims for amoxicillin, amoxicillin\/clavulanic acid, cefadroxil, cephalexin, clindamycin, doxycycline, mupirocin, penicillin V, and sulfamethoxazole\/trimethoprim significantly increased, whereas use of azithromycin, ciprofloxacin, levofloxacin, and vancomycin significantly decreased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05). Claims for opioids decreased from 3,224,572 (2013) to 2,070,423 (2021). Use of hydrocodone\/acetaminophen, oxycodone\/acetaminophen, and tramadol\/acetaminophen also significantly decreased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05). Use of oxycodone and oxycodone myristate significantly increased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05). Claims for fentanyl, methadone, and morphine all significantly decreased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05). Claims for NSAIDs increased from 1,300,279 (2013) to 1,796,419 (2021). Claims for celecoxib, diclofenac, ibuprofen, ketorolac, and meloxicam all significantly increased, whereas claims for etodolac, indomethacin, nabumetone, naproxen, piroxicam, and sulindac all significantly decreased (\n              <jats:italic toggle=\"yes\">P<\/jats:italic>\n              &lt;0.05).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In line with national guidelines, claims for NSAIDs are increasing and claims for opioid pain medications and AOMs are decreasing. Claims for outpatient antibiotics are increasing, which is of significant concern, given renewed focus on antibiotic stewardship.<\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/01477447-20250702-03","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T17:10:32Z","timestamp":1754932232000},"page":"297-304","source":"Crossref","is-referenced-by-count":1,"title":["Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013\u20132021"],"prefix":"10.3928","volume":"48","author":[{"given":"John","family":"Bartoletta","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery and Sports Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kubsad","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Washington, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Sports Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Chansky","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Sports Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Manner","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Sports Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery and Sports Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1464"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2010\/13\/401"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-22-00047"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2021.01.051"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.01.014"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.4151"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.15.01494"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sopen.2019.05.008"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27101"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_1_12_2","volume-title":"Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review","author":"Fink HA","year":"2019","unstructured":"Fink HA, MacDonald R, Forte ML, . Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review[Internet]. Agency for Health-care Research and Quality (US); 2019 Apr. (Comparative Effectiveness Review, No. 218.) Table 1, U.S. FDA approved drugs used for osteoporosis treatment and prevention. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542722\/table\/ch2.tab1\/"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3339-z"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0660-6"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.E.00449"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1308\/003588406X116891"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001831"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000001152"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2024.04.024"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab475"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-22-12-772"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","unstructured":"Acu\u00f1a AJ Jella TK Samuel LT Cwalina TB Kim TS Kamath AF. A work in progress: national opioid prescription reductions across orthopaedic subspecialties in a contemporary Medicare sample of 5 026 911 claims. J Am Acad Orthop Surg Glob Res Rev. 2021;5(5):e21.00080. 10.5435\/JAAOSGlobal-D-21-00080","DOI":"10.5435\/JAAOSGlobal-D-21-00080"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjan.2016.01.005"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7141.1390"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOS-D-17-00727"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.13383"},{"issue":"3","key":"e_1_3_1_27_2","first-page":"e61","article-title":"Trends in opioid and nonsteroidal anti-inflammatory use and adverse events","volume":"24","author":"Fassio V","year":"2018","unstructured":"Fassio V, Aspinall SL, Zhao X, . Trends in opioid and nonsteroidal anti-inflammatory use and adverse events. Am J Manag Care. 2018;24(3):e61\u2013e72. PMID:29553279","journal-title":"Am J Manag Care"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.21.00466"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12178-017-9406-7"}],"container-title":["Orthopedics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:18:31Z","timestamp":1758053911000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/01477447-20250702-03"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.3928\/01477447-20250702-03"],"URL":"https:\/\/doi.org\/10.3928\/01477447-20250702-03","relation":{},"ISSN":["0147-7447","1938-2367"],"issn-type":[{"value":"0147-7447","type":"print"},{"value":"1938-2367","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}